renal-cell-carcinoma

Documents about renal-cell-carcinoma

• Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer#885658ClinicalTrials.gov
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer#868910ClinicalTrials.gov
• A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma#866150ClinicalTrials.gov
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform#121327ClinicalTrials.gov
• Biomarkers of Renal Cancer#982323ClinicalTrials.gov
• ITIL-306 in Advanced Solid Tumors#226274ClinicalTrials.gov
• 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.#230426ClinicalTrials.gov
• 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC#870356ClinicalTrials.gov
• Involvement of PBRM1 in VHL disease‑associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway#268500HAL (France)
• Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)#874939ClinicalTrials.gov
• AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib#969871ClinicalTrials.gov
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma#981814ClinicalTrials.gov
• Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...#851674ClinicalTrials.gov
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers#300257ClinicalTrials.gov
• ペムブロリズマブ・レンバチニブ併用療法開始後に免疫関連有害事象による致死的な脳炎を発症した淡明細胞型腎細胞癌の1例#262545Kyoto University Research Information Repository
• ペムブロリズマブ・レンバチニブ併用療法開始後に免疫関連有害事象による致死的な脳炎を発症した淡明細胞型腎細胞癌の1例#262552Kyoto University Research Information Repository
• A Rollover Protocol for Subjects Previously Treated With AGS-003#303729ClinicalTrials.gov
• NeoVax Plus Ipilimumab in Renal Cell Carcinoma#895829ClinicalTrials.gov
• Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma.#785667NCBI PubMed Central
• pazopanib_NCRCC,Ph2 STUDY#831317ClinicalTrials.gov
• SLM + Axitinib for Clear Cell RCC#910572ClinicalTrials.gov
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer#837059ClinicalTrials.gov
• Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy#847077ClinicalTrials.gov
• Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer#867644ClinicalTrials.gov
• A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors#407735ClinicalTrials.gov
• A Study of rSIFN-co in Subjects With Advanced Solid Tumors#919025ClinicalTrials.gov
• Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC#918781ClinicalTrials.gov
• Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors#136314ClinicalTrials.gov
• Predictors for Recurrences Within One Year Following Radical Nephrectomy for Non-metastatic Renal Cell Carcinomas#345347OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)#908825ClinicalTrials.gov
• A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI#424183ClinicalTrials.gov
• Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)#864543ClinicalTrials.gov
• Towards a better understanding of kidney cancer: genetically engineered mouse models and biomarkers insights#257739HAL (France)
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation#417534ClinicalTrials.gov
• Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors#1033000ClinicalTrials.gov
• Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subjects With RCC#865379ClinicalTrials.gov
• Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer#152484ClinicalTrials.gov
• Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer#279495ClinicalTrials.gov
• The Incidence of Pulmonary Embolism During Nephrectomy#847387ClinicalTrials.gov
• The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts.#991952ClinicalTrials.gov
• Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies#846967ClinicalTrials.gov
• Image 2_NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.jpg#405488Figshare
• Image 3_NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.jpg#405489Figshare
• Table 2_NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.xlsx#405490Figshare
• Image 1_NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.jpg#405491Figshare
• Table 1_NECSO-based classification predicts immunotherapy efficacy and identifies FLAD1 as therapeutic target in kidney renal clear cell carcinoma.xlsx#405492Figshare
• Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma#904139ClinicalTrials.gov
• Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.#388785NCBI PubMed Central
• First-Line Treatment Strategies in IMDC Favourable-Risk Metastatic Clear Cell Renal Cell Carcinoma.#402575NCBI PubMed Central
• A spatial multi-omic portrait of survival outcome for clear cell renal cell carcinoma#414793Europe PMC